Potassium bicarbonate/potassium citrate - Advicenne

Drug Profile

Potassium bicarbonate/potassium citrate - Advicenne

Alternative Names: ADV 7103; Potassium citrate monohydrated/potassium hydrogen carbonate - Advicenne; Potassium citrate/potassium bicarbonate - Advicenne; Potassium hydrogen carbonate/potassium citrate monohydrated - Advicenne

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Advicenne
  • Class Alkalinising agents; Citrates; Electrolytes; Potassium compounds; Small molecules; Urologics
  • Mechanism of Action Electrolyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Kidney disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase III Kidney disorders

Most Recent Events

  • 06 Nov 2017 Efficacy data from a phase III open-label extension trial in Kidney disorders (distal renal tubular acidosis) released by Advicenne
  • 06 Nov 2017 Advicenne plans a pivotal phase II/III trial for Kidney disorders (Cystinuria) in Europe in 2018
  • 06 Nov 2017 Advicenne announces intention to submit MAA to European Medicines Agency for Kidney disorders (distal renal tubular acidosis) in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top